Arrhythmia

Johnson & Johnson MedTech Acquires Laminar, Inc.

Retrieved on: 
Thursday, November 30, 2023

Johnson & Johnson MedTech1 today announced the completion of the acquisition2 of Laminar, Inc., a privately-held medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib).

Key Points: 
  • Johnson & Johnson MedTech1 today announced the completion of the acquisition2 of Laminar, Inc., a privately-held medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib).
  • Johnson & Johnson MedTech acquired Laminar for an upfront payment of $400 million, subject to customary adjustments, with additional potential clinical and regulatory milestone payments in 2024 and beyond.
  • Laminar joins Johnson & Johnson MedTech as part of Biosense Webster, Inc. – a global leader in cardiac arrhythmia treatment.
  • “We are looking forward to advancing this vision as part of Johnson & Johnson MedTech.”
    “We are excited to welcome Laminar to Johnson & Johnson MedTech,” said Jasmina Brooks, President, Biosense Webster.

Investigators at Children’s Hospital Los Angeles Find Heart Complications in Many Children Treated for MIS-C

Retrieved on: 
Wednesday, November 15, 2023

Investigators at Children’s Hospital Los Angeles analyzed results of follow-up cardiac studies for all children who had been hospitalized at CHLA for MIS-C.

Key Points: 
  • Investigators at Children’s Hospital Los Angeles analyzed results of follow-up cardiac studies for all children who had been hospitalized at CHLA for MIS-C.
  • They found that many patients with MIS-C had abnormal findings on at least one cardiac study at their 6-month follow-up.
  • Using exercise stress testing , the investigators saw a number of children who had lower than expected exercise capacity.
  • However, if the damage is permanent, these kids are potentially at lifelong risk of early heart disease.

HeartBeam Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023

“During the third quarter of 2023 we significantly enhanced the HeartBeam team, continued to make steady progress toward upcoming clinical and regulatory milestones, and validated the potential of our VECG technology platform,” said Branislav Vajdic, PhD, Chief Executive Officer and Founder of HeartBeam.

Key Points: 
  • “During the third quarter of 2023 we significantly enhanced the HeartBeam team, continued to make steady progress toward upcoming clinical and regulatory milestones, and validated the potential of our VECG technology platform,” said Branislav Vajdic, PhD, Chief Executive Officer and Founder of HeartBeam.
  • Research and development expenses for the third quarter of 2023 were $1.6 million, compared to $1.6 million for the third quarter of 2022.
  • General and administrative expenses for the third quarter of 2023 were $2.1 million compared to $2.0 million for the third quarter of 2022.
  • Net loss for the third quarter of 2023 was $3.5 million, compared to a net loss of $3.6 million for the third quarter of 2022.

Anthos Therapeutics' Novel Dual-Acting Factor XI/XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation

Retrieved on: 
Sunday, November 12, 2023

Anthos Therapeutics has initiated an extension study to enable patients to transition from rivaroxaban to abelacimab to benefit from the improved bleeding profile.

Key Points: 
  • Anthos Therapeutics has initiated an extension study to enable patients to transition from rivaroxaban to abelacimab to benefit from the improved bleeding profile.
  • Although currently available anticoagulants are effective in preventing strokes in patients with atrial fibrillation, the risk of bleeding remains an issue.
  • “Based on the evidence to date, we are highly confident that abelacimab will offer a potential game-changing treatment approach for patients with atrial fibrillation."
  • Abelacimab is an investigational agent and is not approved for any indication in any country.

Global Holter Monitor Market Insights Report 2023: Market was Valued at $742.61 Million in 2023 and is Expected to Reach $1.20 Billion by 2029 - ResearchAndMarkets.com

Retrieved on: 
Friday, November 10, 2023

The "Global Holter Monitor Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Holter Monitor Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering.
  • The global Holter Monitor market was valued at $742.61 million in 2023 and is expected to reach $1,208.08 million by 2029, growing at a CAGR of 8.45%.
  • The study considers a detailed scenario of the present global Holter monitor market and its market dynamics for 2024-2029.
  • Among the different channel types, the Holter monitor with three channels dominated the market in 2023, accounting for 49.06% of the market share.

Exciting New Applications of vMap for Ventricular Arrhythmias Highlighted at AHA 2023

Retrieved on: 
Friday, November 10, 2023

In 32 consecutive VT patients, 26 had unstable VT. All 26 unstable VT patients successfully underwent vMap’s arrhythmia analysis and received guided VT ablation.

Key Points: 
  • In 32 consecutive VT patients, 26 had unstable VT. All 26 unstable VT patients successfully underwent vMap’s arrhythmia analysis and received guided VT ablation.
  • In the second study, “Novel Pre-Operative Non-Invasive Computational 12-Lead ECG Mapping to Facilitate Surgical Ablation of Ventricular Arrhythmias,” Dr. Ho introduces a novel workflow that utilizes pre-operative use of vMap to localize ventricular arrhythmias in patients undergoing cardiac surgery.
  • "These studies exemplify the strides we are taking to advance the care of patients with ventricular arrhythmias.
  • November 12, 2023, 12:30 PM – 12:35 PM, Moderated Digital Posters 4, Science and Technology Hall, Level 2
    November 12, 2023, 3.30 PM – 4.45 PM, Zone 2, Science and Technology Hall, Level 2

Lucem Health Introduces Reveal for Stroke to Accelerate Treatment of AFib-Related Stroke Risks

Retrieved on: 
Wednesday, December 13, 2023

DAVIDSON, N.C., Dec. 13, 2023 /PRNewswire/ -- Lucem Health™, a leader in AI-driven early disease detection solutions, announced today the release of Reveal for Stroke, an innovative solution designed to identify patients with undocumented atrial fibrillation (AFib) and higher risk of AFib-related strokes. As noted by the American Heart Association, AFib affects 2.7-6.1 million individuals in the US and significantly increases the risk of ischemic stroke. Thus, the need for early identification and intervention has never been more critical.

Key Points: 
  • However, at least one-in-five AFib cases remain undocumented in clinical practice, leading to many patients missing out on important stroke prevention treatment.
  • "At Lucem Health, we develop solutions that identify patients with major health risks that are hiding in plain sight.
  • Lucem Health has partnered with AccurKardia, a renowned ECG-led diagnostics company, to develop Reveal for Stroke.
  • "Reveal for Stroke represents a shared vision with Lucem Health to harness the full potential of ECG data in managing stroke risks.

Lucem Health Introduces Reveal for Stroke to Accelerate Treatment of AFib-Related Stroke Risks

Retrieved on: 
Wednesday, December 13, 2023

DAVIDSON, N.C., Dec. 13, 2023 /PRNewswire/ -- Lucem Health™, a leader in AI-driven early disease detection solutions, announced today the release of Reveal for Stroke, an innovative solution designed to identify patients with undocumented atrial fibrillation (AFib) and higher risk of AFib-related strokes. As noted by the American Heart Association, AFib affects 2.7-6.1 million individuals in the US and significantly increases the risk of ischemic stroke. Thus, the need for early identification and intervention has never been more critical.

Key Points: 
  • However, at least one-in-five AFib cases remain undocumented in clinical practice, leading to many patients missing out on important stroke prevention treatment.
  • "At Lucem Health, we develop solutions that identify patients with major health risks that are hiding in plain sight.
  • Lucem Health has partnered with AccurKardia, a renowned ECG-led diagnostics company, to develop Reveal for Stroke.
  • "Reveal for Stroke represents a shared vision with Lucem Health to harness the full potential of ECG data in managing stroke risks.

Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting

Retrieved on: 
Tuesday, December 12, 2023

These data, which were presented in oral and poster presentations at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, continue to support the role of pirtobrutinib in the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL).

Key Points: 
  • These data, which were presented in oral and poster presentations at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, continue to support the role of pirtobrutinib in the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL).
  • The labeling for pirtobrutinib contains warnings and precautions for infections, hemorrhage, cytopenias, cardiac arrhythmias, second primary malignancies, and embryo-fetal toxicity.
  • The BRUIN Phase 1/2 clinical trial is evaluating pirtobrutinib in patients previously treated for MCL, CLL/SLL, or other non-Hodgkin lymphomas (NHL).
  • All presentations of safety and efficacy data from the BRUIN Phase 1/2 trial utilized a cutoff date of May 5, 2023.

Ajax Health Establishes Cortex, a Comprehensive AFib Ablation Technology Company, with $90 Million Investment Led by KKR and Hellman & Friedman

Retrieved on: 
Thursday, December 7, 2023

MENLO PARK, Calif., Dec. 7, 2023 /PRNewswire/ -- Ajax Health announced today the formation and funding of Cortex, a medical technology company developing an integrated mapping and ablation solution suite for the treatment of atrial fibrillation (AFib), the most common heart rhythm disorder, affecting more than 30 million patients worldwide. Cortex has raised $90 million in funding commitments led by KKR and Hellman & Friedman (H&F) with participation by other investors including AI Life Sciences, an affiliate of Access Industries.

Key Points: 
  • Cortex has raised $90 million in funding commitments led by KKR and Hellman & Friedman (H&F) with participation by other investors including AI Life Sciences, an affiliate of Access Industries.
  • Cortex brings together expert teams with complementary innovations in electrophysiology to accelerate the continued development and clinical validation of next-generation ablation solutions and differentiated AFib mapping technology.
  • "Cortex's vision is to enable more intelligent AFib treatment," said Duke Rohlen, CEO of Ajax Health and CEO of Cortex.
  • EGF mapping allows physicians to detect AFib sources and is designed to support personalized ablation therapy to potentially improve outcomes.